1、ppt made by leeyongChemotherapy used in IALT Adjuvant chemotherapy regimen%of the ptsCisplatin 300-400mg/m2 over 3-4 cycles withetoposidevinovelbinevinblastinvindesine5627116Chemotherapy armControlP valueMedian survival50.8 months44.4 months0.035-year survival rate44.5%40.4%Median disease-free survi
2、val40.2 months 30.5 months0.0035-year disease-free survival rate39.4%34.3%Lethal toxicity rate0.8%0The overall survival hazard ratio for chemotherapy was 0.86 95%CI=0.76-0.98Absolute 5-year survival benefit of 4.1%Absolute 5-year disease-free survival benefit of 5.1%,and hazard ratio was o.83%Size a
3、nd hazard ratio of overall survival in recent large adjuvant studiesHazard ratio for chemotherapy95%CInNSCLCCG1,394o.870.74-1.02ALPI1,2090.960.81-1.13IALT1,8690.860.76-0.98BLT3811.020.77-1.35Comparison of every-3-weeks versus weekly docetaxelDocetaxel 75mg/m2every 3 weeksDocetaxel 36mg/m2weeklyP val
4、ueResponse rate8%5%NSTTP2.7 months2.9 monthsNS1-year survival rate29.2%21.8%NSMedian survival7.1 months5.4 monthso.o4Comparison of every-3-weeks versus weekly docetaxelPemetrexed versus DocetaxelEfficacy of pemetrexed versus docetaxelMedian survivalHazard ratio(95%CI)Pemetrexed(n=283)Docetaxel(n=288
5、)1-year survival rateTime to progressionHazard ratio(95%CI)Response rate8.3 months7.9 monthso.99(0.8-1.2)29.7%29.7%2.9 months2.9 months0.97(0.8-1.2)9.1%8.8%Grade toxicity of pts of pemetrexed versus docexelPemetrxedn=285DocetaxelN=276P valueNeutropeniaNeutropenia feverThrombcytopeniaNeuropathy(grade
6、 2-4)Hospitalization due to Fever and neutropenia5%2%2%3%2%40%13%1%8%16%0.00010.0001o.1160.0140.0001Gefitinib(Irresa)Safety and TolerabilityGefitinib(Irresa)Pts with BAC and never smokePts with either non-smoker or BAC histology Pts who were smoker with non-BAC histologyRRMST55%14 months26%9 months6%4 months Pts with nonadenocacinoma0Memorial Sloan-Kettering Cancer CenterGefitinib(Irresa)
